ABCB1 and cancer: As the emergence of therapy resistance is generally viewed as an evolutionary process in which cancer cells adapt to selection pressures mediated by cytotoxic drugs, this study has specifically focused on elucidating the underlying biology of drug-resistant ABCB1 fusion-positive cells and how this distinctive phenotype, in combination with evolutionary dynamics, can be clinically exploited.